Apixaban Enhances Endogenous Fibrinolysis in Patients with Atrial Fibrillation

Nikolaos Spinthakis, Ying X. Gue, Mohamed Farag, Manivannan Srinivasan, David Wellsted, Gregory Y H Lip, Deepa RJ Arachchillage, Diana Gorog

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)
59 Downloads (Pure)


AIMS: Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial recanalization, attributable to endogenous fibrinolysis, which strongly relates to improved functional outcome. The impact of oral anticoagulants on endogenous fibrinolysis is unknown. Our aim was to test the hypothesis that apixaban enhances endogenous fibrinolysis in non-valvular atrial fibrillation (NVAF). METHODS AND RESULTS: In a prospective cross-sectional analysis, we compared endogenous fibrinolysis in NVAF patients (n = 180) taking aspirin, warfarin, or apixaban. In a prospective longitudinal study, patients were tested before and after apixaban (n = 80). Endogenous fibrinolysis was assessed using the Global Thrombosis Test (GTT) and thromboelastography (TEG). Endogenous fibrinolysis [measured by GTT lysis time (LT)] was shorter on apixaban compared with warfarin or aspirin [median 1850 (IQR 1591-2300) vs. 2758 (2014-3502) vs. 2135 (1752-2463) s, P < 0.0001]. Among TEG indices, a small but significant difference in clot lysis time (CLT) was observed [apixaban 60.0 (45.0-61.0) vs. warfarin 61.0 (57.0-62.0) vs. aspirin 61.0 (59.0-61.0) min, P = 0.036]. Apixaban improved endogenous fibrinolysis measured using the GTT [LT pre-treatment 2204 (1779-2738) vs. on-treatment 1882 (1607-2374) s, P = 0.0003], but not by using TEG. Change in LT (ΔLT) with apixaban correlated with baseline LT (r = 0.77, P < 0.0001). There was weak correlation between ΔLT and ΔCLT in response to apixaban (r = 0.28, P = 0.02) and between on-apixaban LT and CLT (r = 0.25, P = 0.022). CONCLUSION: Apixaban enhances endogenous fibrinolysis, with maximal effect in those with impaired fibrinolysis pre-treatment. Apixaban-treated patients exhibit more favourable fibrinolysis profiles than those taking warfarin or aspirin. Whether apixaban may confer additional thrombotic risk reduction in NVAF patients with impaired fibrinolysis, compared to warfarin, merits further study.
Original languageEnglish
Pages (from-to)1297-1306
Number of pages10
JournalEP Europace
Issue number9
Early online date25 Jun 2019
Publication statusPublished - 1 Sept 2019


  • Apixaban
  • Atrial fibrillation
  • Endogenous fibrinolysis
  • Non-vitamin K antagonist oral anticoagulant
  • Thrombosis


Dive into the research topics of 'Apixaban Enhances Endogenous Fibrinolysis in Patients with Atrial Fibrillation'. Together they form a unique fingerprint.

Cite this